Raymond James Financial’s Integra LifeSciences IART Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.32M Buy
326,731
+52,270
+19% +$902K ﹤0.01% 2680
2026
Q2
$4.93M Buy
274,461
+6,535
+2% +$91.4K ﹤0.01% 2745
2026
Q1
$2.52M Buy
267,926
+850
+0.3% +$9.33K ﹤0.01% 3168
2025
Q4
$3.32M Buy
267,076
+48,599
+22% +$646K ﹤0.01% 2846
2025
Q3
$3.13M Buy
218,477
+171,286
+363% +$2.35M ﹤0.01% 2820
2025
Q2
$579K Sell
47,191
-506
-1% -$7.35K ﹤0.01% 3926
2025
Q1
$1.05M Buy
47,697
+6,105
+15% +$144K ﹤0.01% 3453
2024
Q4
$943K Buy
+41,592
New +$908K ﹤0.01% 3488

Other funds holding IART

Raymond James Financial's IART Position: Q3 2026 in Review

Raymond James Financial increased its Integra LifeSciences (IART) stake by 19% in Q3 2026, buying an estimated $902K and bringing the position to 326,731 shares worth $5.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2680.

Raymond James Financial first reported a position in IART in Q4 2024 and has held it in 8 quarters since. 234 funds tracked by Wall St. Rank hold IART as of Q3 2026.

  • Raymond James Financial held 326,731 shares of Integra LifeSciences worth $5.32M as of Q3 2026.
  • Raymond James Financial bought 52,270 Integra LifeSciences shares in Q3 2026, an estimated $902K.
  • Integra LifeSciences made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #2680 holding.
  • Raymond James Financial first reported a position in Integra LifeSciences in Q4 2024 and has held it in 8 quarters since.
  • 234 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.